首页> 外国专利> SYNERGISTIC COMBINATION OF IL4 RECEPTOR TARGETED AGENTS, INTERFERON GAMMA, AND INTERFERON ALPHA FOR USE IN TREATING OVARIAN CANCER

SYNERGISTIC COMBINATION OF IL4 RECEPTOR TARGETED AGENTS, INTERFERON GAMMA, AND INTERFERON ALPHA FOR USE IN TREATING OVARIAN CANCER

机译:IL4受体靶向剂,干扰素γ和干扰素α的协同组合用于治疗卵巢癌

摘要

Methods and compositions are disclosed for treating a subject with a cancer. The compositions can include a chimeric molecule comprising an agent that specifically binds the interleukin 4 receptor (IL-4R) and a toxic moiety, an interferon alpha (IFNa), and an interferon gamma (IFNy). In some non-liming embodiments, the compositions can also include monocytes. The methods disclosed herein include administering a therapeutically effective amount of the compositions taught herein to a subject with cancer, thereby treating the cancer in the subject, wherein cells in the cancer express IL-4R. In some non-liming embodiments, the methods can also include administering monocytes.
机译:公开了用于治疗患有癌症的受试者的方法和组合物。所述组合物可包括嵌合分子,其包含特异性结合白介素4受体(IL-4R)和毒性部分的试剂,干扰素α(IFNa)和干扰素γ(IFNγ)。在一些非限制性实施方案中,所述组合物还可包含单核细胞。本文公开的方法包括向患有癌症的受试者施用治疗有效量的本文教导的组合物,从而治疗所述受试者的癌症,其中所述癌症中的细胞表达IL-4R。在一些非限制性实施方案中,该方法还可包括施用单核细胞。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号